Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)

TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth, subject to individual plan eligibility and reimbursement requirements. “Reimbursement decisions from private payers help determine whether a treatment is a real option for families,” said Claire Zlobin, Founder, Life With A Baby. “It’s exciting to see that most p